uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies

Chardan Capital Markets Reiterates Buy on uniQure (QURE) Following New FDA Guidelines on Gene Therapy

May 23, 2018 8:41 AM EDT

Chardan Capital Markets reiterated a Buy rating and $50.00 price target on uniQure BV (NASDAQ: QURE) following the FDA commissioner's statement that surrogate endpoints like factor levels, rather than bleed rates, may become the standard for approval of gene therapies for hemophilia. Analyst... More